pharma · Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) · IgA Nephropathy (IgAN) · VERA
Vera Therapeutics
VERALOX Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker VERA. Primary therapeutic focus areas include Recurrent Low-Grade Serous Ovarian Cancer (LGSOC), IgA Nephropat
4539 Metropolitan Ct, Frederick, Maryland 21704, US HQ
2018 Founded
9 Employees
Public company Type
VERA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4539 Metropolitan Ct, Frederick, Maryland 21704, US
- Founded
- 2018
- Employees
- 9
- Programs
- 25
- Drugs
- 32
- Patents
- 140
CYP2C19 genotyping
Approved · gene therapy · Myocardial Infarction
CYP2C19 genotyping for Myocardial Infarction is a Approved program (gene_therapy) at Vera Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code PGxSTEMI08
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vera Therapeutics
- Phase
- Approved
- Modality
- gene_therapy
- Indication
- Myocardial Infarction
- Status
- completed
- Trials
- 1